



MannKind to Present at Upcoming Conferences

11/02/09

MannKind to Present at Upcoming Conferences

VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 2, 2009-- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- Imperial Capital's 3rd Annual Global Opportunities Conference on Thursday, November 5, 2009 at 2:10 PM (EST) at the New York Palace Hotel in New York, New York
- Lazard Capital Market's 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:10 PM (EST) at the St. Regis Hotel in New York, New York

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA®, MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Source: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com